Evidence map›Paper›PMID 39256838›Full record

ArticleCancer cell international2024

Pan-cancer analysis reveals CCL5/CSF2 as potential predictive biomarkers for immune checkpoint inhibitors.

Yi-Chao Chen, Wei-Zhong Zheng, Chun-Peng Liu, Yong-Qiang Zhao, Jun-Wei Li, Ze-Sen Du, Tian-Tian Zhai, Hao-Yu Lin, Wen-Qi Shi, Shan-Qing Cai and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Cancers · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yi-Chao Chen *Clinical Research Center, Shantou Central Hospital, Shantou, 515041, China.
Wei-Zhong Zheng *School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, 999077, China.
Chun-Peng Liu *Department of Pathology, Shantou Central Hospital, Shantou, 515041, China.
Yong-Qiang ZhaoDepartment of Pathology, Shantou Central Hospital, Shantou, 515041, China.
Jun-Wei LiClinical Research Center, Shantou Central Hospital, Shantou, 515041, China.
Ze-Sen DuSurgical Oncology Department, Shantou Central Hospital, Shantou, 515041, China.
Tian-Tian ZhaiRadiation Oncology Department, The Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Hao-Yu LinDepartment of Thyroid and Breast Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China.
Wen-Qi ShiClinical Research Center, Shantou Central Hospital, Shantou, 515041, China.
Shan-Qing CaiDepartment of Pathology, Shantou Central Hospital, Shantou, 515041, China.
Feng PanClinical Research Center, Shantou Central Hospital, Shantou, 515041, China. panfengbio@126.com.
Si-Qi QiuClinical Research Center, Shantou Central Hospital, Shantou, 515041, China. s_patrick@163.com.

Funding

Cancer Hospital of Shantou University Medical College, China 2020A001Department of Education of Guangdong Province, China 2019KQNCX032Natural Science Foundation Committee, China 81901801Natural Science Foundation Committee, China 82003221Natural Science Foundation Committee, China 82173011Natural Science Foundation of Guangdong Province, China 2019A1515010239Natural Science Foundation of Guangdong Province, China 2021A1515011180Science and technology projects of Shantou, China 200601155261081Shantou Central Hospital Research Incubation Program, China 201905
6 · The paper itself

Abstract

backgroundCurrently, there are no optimal biomarkers available for distinguishing patients who will respond to immune checkpoint inhibitors (ICIs) therapies. Consequently, the exploration of novel biomarkers that can predict responsiveness to ICIs is crucial in the field of immunotherapy.

methodsWe estimated the proportions of 22 immune cell components in 10 cancer types (6,128 tumors) using the CIBERSORT algorithm, and further classified patients based on their tumor immune cell proportions in a pan-cancer setting using k-means clustering. Differentially expressed immune genes between the patient subgroups were identified, and potential predictive biomarkers for ICIs were explored. Finally, the predictive value of the identified biomarkers was verified in patients with urothelial carcinoma (UC) and esophageal squamous cell carcinoma (ESCC) who received ICIs.

resultsOur study identified two subgroups of patients with distinct immune infiltrating phenotypes and differing clinical outcomes. The patient subgroup with improved outcomes displayed tumors enriched with genes related to immune response regulation and pathway activation. Furthermore, CCL5 and CSF2 were identified as immune-related hub-genes and were found to be prognostic in a pan-cancer setting. Importantly, UC and ESCC patients with high expression of CCL5 and low expression of CSF2 responded better to ICIs.

conclusionWe demonstrated CCL5 and CSF2 as potential novel biomarkers for predicting the response to ICIs in patients with UC and ESCC. The predictive value of these biomarkers in other cancer types warrants further evaluation in future studies.

Indexed as

BiomarkersCCL5CIBERSORTCSF2Immune checkpoint inhibitorsPan-cancer analysis

Identifiers

PMID39256838
PMCPMC11389493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.